

B Kevin Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1621593/publications.pdf>

Version: 2024-02-01

136
papers

10,277
citations

41344

49
h-index

34986

98
g-index

144
all docs

144
docs citations

144
times ranked

11548
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2572-2588.	2.4	11
2	Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells. <i>Scientific Reports</i> , 2021, 11, 2932.	3.3	5
3	Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models. <i>Toxicology in Vitro</i> , 2021, 72, 105096.	2.4	10
4	Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification. <i>Archives of Toxicology</i> , 2021, 95, 2413-2430.	4.2	2
5	Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening. <i>Hepatology</i> , 2021, 74, 513-515.	7.3	2
6	Deciphering Adverse Drug Reactions: <i>In Vitro</i> Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. <i>Toxicological Sciences</i> , 2021, 183, 139-153.	3.1	9
7	Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration. <i>Hepatology</i> , 2021, 74, 973-986.	7.3	29
8	Systems analysis of miRNA biomarkers to inform drug safety. <i>Archives of Toxicology</i> , 2021, 95, 3475-3495.	4.2	14
9	Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury. <i>Chemical Research in Toxicology</i> , 2020, 33, 61-76.	3.3	17
10	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 131-148.	46.4	153
11	Characterization of Clozapine-Responsive Human T Cells. <i>Journal of Immunology</i> , 2020, 205, 2375-2390.	0.8	9
12	Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374.	5.4	17
13	Cell Membrane Transporters Facilitate the Accumulation of Hepatocellular Flucloxacillin Protein Adducts: Implication in Flucloxacillin-Induced Liver Injury. <i>Chemical Research in Toxicology</i> , 2020, 33, 2939-2943.	3.3	7
14	The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine. <i>Toxicology and Applied Pharmacology</i> , 2020, 403, 115163.	2.8	8
15	CDDO-imidazole Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9965-9976.	6.4	28
16	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. <i>Toxicological Sciences</i> , 2020, 178, 115-126.	3.1	14
17	Alternatively activated macrophages promote resolution of necrosis following acute liver injury. <i>Journal of Hepatology</i> , 2020, 73, 349-360.	3.7	97
18	A Noninvasive Imaging Toolbox Indicates Limited Therapeutic Potential of Conditionally Activated Macrophages in a Mouse Model of Multiple Organ Dysfunction. <i>Stem Cells International</i> , 2019, 2019, 1-13.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Differential toxic effects of bile acid mixtures in isolated mitochondria and physiologically relevant HepaRG cells. <i>Toxicology in Vitro</i> , 2019, 61, 104595.	2.4	16
20	Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System. <i>Hepatology</i> , 2019, 70, 1732-1749.	7.3	33
21	Acute Metabolic Switch Assay Using Glucose/Galactose Medium in HepaRG Cells to Detect Mitochondrial Toxicity. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , 2019, 80, e76.	1.1	12
22	Stem cell models as an <i>in vitro</i> model for predictive toxicology. <i>Biochemical Journal</i> , 2019, 476, 1149-1158.	3.7	21
23	Dapsone and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1533-1548.	5.7	37
24	Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. <i>Archives of Toxicology</i> , 2019, 93, 385-399.	4.2	23
25	Characterization of Healthy Donor-Derived T-Cell Responses Specific to Telaprevir Diastereomers. <i>Toxicological Sciences</i> , 2019, 168, 597-609.	3.1	3
26	Application of <i>in Vitro</i> T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity. <i>Chemical Research in Toxicology</i> , 2018, 31, 165-167.	3.3	16
27	Innovative organotypic <i>in vitro</i> models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms. <i>Archives of Toxicology</i> , 2018, 92, 557-569.	4.2	35
28	β -Lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 235-249.e8.	2.9	34
29	Kinetic characterization of bile salt transport by human NTCP (SLC10A1). <i>Toxicology in Vitro</i> , 2018, 46, 189-193.	2.4	16
30	Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 104-113.	8.1	99
31	The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. <i>Oncotarget</i> , 2018, 9, 27104-27116.	1.8	40
32	Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop. <i>Regenerative Medicine</i> , 2018, 13, 935-944.	1.7	12
33	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. <i>Chemical Research in Toxicology</i> , 2018, 31, 1022-1024.	3.3	9
34	Human OATP1B1 (SLCO1B1) transports sulfated bile acids and bile salts with particular efficiency. <i>Toxicology in Vitro</i> , 2018, 52, 189-194.	2.4	12
35	TEMPORARY REMOVAL: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. <i>Journal of Hepatology</i> , 2018, , .	3.7	4
36	The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity. <i>Toxicology in Vitro</i> , 2018, 53, 136-147.	2.4	33

#	ARTICLE	IF	CITATIONS
37	Model-based identification of TNF α -induced IKK β -mediated and I κ B α -mediated regulation of NF κ B signal transduction as a tool to quantify the impact of drug-induced liver injury compounds. <i>Npj Systems Biology and Applications</i> , 2018, 4, 23.	3.0	19
38	Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. <i>Archives of Toxicology</i> , 2017, 91, 439-452.	4.2	98
39	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19
40	Identification of drug- and drug-metabolite immune responses originating from both naive and memory T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 578-581.e5.	2.9	10
41	Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance α -based detection in vivo. <i>Cytotherapy</i> , 2017, 19, 555-569.	0.7	44
42	Definition of the Nature and Hapten Threshold of the β -Lactam Antigen Required for T Cell Activation In Vitro and in Patients. <i>Journal of Immunology</i> , 2017, 198, 4217-4227.	0.8	54
43	Donor-Dependent and Other Nondefined Factors Have Greater Influence on the Hepatic Phenotype Than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1321-1331.	3.3	16
44	Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 767-782.	3.3	30
45	Dapsone and Nitroso Dapsone Activation of Na α β -T-Cells from Healthy Donors. <i>Chemical Research in Toxicology</i> , 2017, 30, 2174-2186.	3.3	18
46	Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies. <i>Npj Regenerative Medicine</i> , 2017, 2, 28.	5.2	47
47	Circulating levels of miR-122 increase post-mortem, particularly following lethal dosing with pentobarbital sodium: implications for pre-clinical liver injury studies. <i>Toxicology Research</i> , 2017, 6, 406-411.	2.1	3
48	Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from Epoxide Metabolites of Carbamazepine in Patients. <i>Chemical Research in Toxicology</i> , 2017, 30, 1419-1435.	3.3	22
49	Dynamic and accurate assessment of acetaminophen-induced hepatotoxicity by integrated photoacoustic imaging and mechanistic biomarkers in vivo. <i>Toxicology and Applied Pharmacology</i> , 2017, 332, 64-74.	2.8	20
50	Real-time in vivo imaging reveals localised Nrf2 stress responses associated with direct and metabolism-dependent drug toxicity. <i>Scientific Reports</i> , 2017, 7, 16084.	3.3	11
51	Assessment of Antipiperacillin IgG Binding to Structurally Related Drug Protein Adducts. <i>Chemical Research in Toxicology</i> , 2017, 30, 2097-2099.	3.3	6
52	The Effect of Inhibitory Signals on the Priming of Drug Hapten α -Specific T Cells That Express Distinct V β 2 Receptors. <i>Journal of Immunology</i> , 2017, 199, 1223-1237.	0.8	41
53	From the Cover: Characterization of Isoniazid-Specific T-Cell Clones in Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury. <i>Toxicological Sciences</i> , 2017, 155, 420-431.	3.1	31
54	Stem cell α -derived models to improve mechanistic understanding and prediction of human drug α -induced liver injury. <i>Hepatology</i> , 2017, 65, 710-721.	7.3	54

#	ARTICLE	IF	CITATIONS
55	New Approaches to Investigate Drug-Induced Hypersensitivity. <i>Chemical Research in Toxicology</i> , 2017, 30, 239-259.	3.3	18
56	A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. <i>Archives of Toxicology</i> , 2017, 91, 1385-1400.	4.2	85
57	Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. <i>Scientific Reports</i> , 2016, 6, 25187.	3.3	502
58	A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. <i>Hepatology</i> , 2016, 64, 1699-1710.	7.3	96
59	Mass Spectrometric and Functional Aspects of Drug-Protein Conjugation. <i>Chemical Research in Toxicology</i> , 2016, 29, 1912-1935.	3.3	48
60	Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. <i>Toxicological Sciences</i> , 2016, 154, 416-429.	3.1	40
61	Co-precipitation of DEAE-dextran coated SPIONs: how synthesis conditions affect particle properties, stem cell labelling and MR contrast. <i>Contrast Media and Molecular Imaging</i> , 2016, 11, 362-370.	0.8	24
62	Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. <i>Hepatology</i> , 2016, 64, 1743-1756.	7.3	100
63	Amoxicillin and Clavulanate Form Chemically and Immunologically Distinct Multiple Haptenic Structures in Patients. <i>Chemical Research in Toxicology</i> , 2016, 29, 1762-1772.	3.3	48
64	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. <i>Archives of Toxicology</i> , 2016, 90, 2979-3003.	4.2	50
65	Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats. <i>Toxicology Letters</i> , 2016, 258, 207-215.	0.8	22
66	Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury. <i>Chemical Research in Toxicology</i> , 2016, 29, 1793-1795.	3.3	11
67	No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury. <i>Chemical Research in Toxicology</i> , 2016, 29, 2111-2113.	3.3	8
68	Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2396-2409.	6.4	37
69	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <i>Clinical Cancer Research</i> , 2016, 22, 1734-1743.	7.0	69
70	From mice to men: Murine models of colorectal cancer for use in translational research. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 94-105.	4.4	34
71	Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen-Induced Liver Injury. <i>Hepatology</i> , 2015, 62, 591-599.	7.3	24
72	Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress. <i>Biochemical Society Transactions</i> , 2015, 43, 657-662.	3.4	40

#	ARTICLE	IF	CITATIONS
73	Measures of kidney function by minimally invasive techniques correlate with histological glomerular damage in SCID mice with adriamycin-induced nephropathy. <i>Scientific Reports</i> , 2015, 5, 13601.	3.3	51
74	Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. <i>Hepatology</i> , 2015, 62, 887-899.	7.3	83
75	Parsing interindividual drug variability: an emerging role for systems pharmacology. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2015, 7, 221-241.	6.6	57
76	Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies. <i>Stem Cells Translational Medicine</i> , 2015, 4, 389-400.	3.3	98
77	Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin. <i>Chemical Research in Toxicology</i> , 2015, 28, 51-58.	3.3	33
78	Characterization of Peroxidases Expressed in Human Antigen Presenting Cells and Analysis of the Covalent Binding of Nitroso Sulfamethoxazole to Myeloperoxidase. <i>Chemical Research in Toxicology</i> , 2015, 28, 144-154.	3.3	22
79	Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. <i>Toxicology and Applied Pharmacology</i> , 2015, 283, 168-177.	2.8	153
80	Promiscuous T-cell responses to drugs and drug-haptens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 474-476.e8.	2.9	41
81	Where are we now with paracetamol?. <i>BMJ, The</i> , 2015, 351, h3705.	6.0	12
82	The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death. <i>Toxicology in Vitro</i> , 2015, 29, 732-740.	2.4	135
83	MicroRNA-122: A Novel Hepatocyte-Enriched in vitro Marker of Drug-Induced Cellular Toxicity. <i>Toxicological Sciences</i> , 2015, 144, 173-185.	3.1	33
84	Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study. <i>Journal of Hepatology</i> , 2015, 63, 634-642.	3.7	56
85	Quantification of Drug-Induced Inhibition of Canalicular Cholyl-L-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging. <i>Toxicological Sciences</i> , 2015, 148, 48-59.	3.1	32
86	Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. <i>Kidney International</i> , 2015, 88, 1261-1273.	5.2	41
87	Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. <i>Toxicological Sciences</i> , 2015, 147, 412-424.	3.1	73
88	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of <i>In Vitro</i> Models. <i>Applied in Vitro Toxicology</i> , 2015, 1, 175-186.	1.1	5
89	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 236-244.	2.9	80
90	Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model. <i>Toxicological Sciences</i> , 2015, 146, 146-156.	3.1	27

#	ARTICLE	IF	CITATIONS
91	Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. <i>Free Radical Biology and Medicine</i> , 2015, 78, 202-212.	2.9	161
92	Mass Spectrometric Characterization of Circulating Covalent Protein Adducts Derived from a Drug Acyl Glucuronide Metabolite: Multiple Albumin Adductions in Diclofenac Patients. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 387-402.	2.5	47
93	Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids. <i>Toxicological Sciences</i> , 2014, 140, 462-469.	3.1	21
94	Negative Regulation by PD-L1 during Drug-Specific Priming of IL-22-Secreting T Cells and the Influence of PD-1 on Effector T Cell Function. <i>Journal of Immunology</i> , 2014, 192, 2611-2621.	0.8	50
95	Safety biomarkers for drug-induced liver injury—current status and future perspectives. <i>Toxicology Research</i> , 2014, 3, 75-85.	2.1	17
96	Negative regulation by Programmed Death Ligand-1 during drug-specific priming of T cells and the influence of Programmed Death-1 on effector T cell function. <i>Clinical and Translational Allergy</i> , 2014, 4, O2.	3.2	0
97	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. <i>Archives of Toxicology</i> , 2013, 87, 1315-1530.	4.2	1,089
98	The Generation, Detection, and Effects of Reactive Drug Metabolites. <i>Medicinal Research Reviews</i> , 2013, 33, 985-1080.	10.5	73
99	Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. <i>Hepatology</i> , 2013, 57, 727-739.	7.3	212
100	The Development of In Vitro Culture Methods to Characterize Primary T-Cell Responses to Drugs. <i>Toxicological Sciences</i> , 2012, 127, 150-158.	3.1	60
101	Loss of Transcription Factor Nuclear Factor-Erythroid 2 (NF-E2) p45-related Factor-2 (Nrf2) Leads to Dysregulation of Immune Functions, Redox Homeostasis, and Intracellular Signaling in Dendritic Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 10556-10564.	3.4	63
102	Haloarene Derivatives of Carbamazepine with Reduced Bioactivation Liabilities: 2-Monohalo and 2,8-Dihalo Derivatives. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9773-9784.	6.4	18
103	In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. <i>Genome Medicine</i> , 2012, 4, 51.	8.2	58
104	Convenient Syntheses of Benzo-Fluorinated Dibenz[<i>b,f</i>]azepines: Rearrangements of Isatins, Acridines, and Indoles. <i>Organic Letters</i> , 2011, 13, 5592-5595.	4.6	30
105	Managing the challenge of chemically reactive metabolites in drug development. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 292-306.	46.4	382
106	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <i>Nature Genetics</i> , 2009, 41, 816-819.	21.4	950
107	Evidence for the Involvement of Carbon-centered Radicals in the Induction of Apoptotic Cell Death by Artemisinin Compounds. <i>Journal of Biological Chemistry</i> , 2007, 282, 9372-9382.	3.4	164
108	Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 973-981.	2.9	104

#	ARTICLE	IF	CITATIONS
109	Drug-Specific T Cells in An HIV-Positive Patient with Nevirapine-Induced Hepatitis. <i>Antiviral Therapy</i> , 2006, 11, 393-395.	1.0	12
110	THE ROLE OF METABOLIC ACTIVATION IN DRUG-INDUCED HEPATOTOXICITY. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 177-202.	9.4	422
111	Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf- α and Tnf-Receptor Levels, and on Metabolic Parameters. <i>Antiviral Therapy</i> , 2004, 9, 879-887.	1.0	6
112	METABOLISM OFFLUORINE-CONTAININGDRUGS. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 443-470.	9.4	550
113	Optimisation of the allylsilane approach to C-10 deoxo carba analogues of dihydroartemisinin: synthesis and in vitro antimalarial activity of new, metabolically stable C-10 analogues. <i>Journal of the Chemical Society, Perkin Transactions 1</i> , 2001, , 2682-2689.	1.3	26
114	Carbamazepine is not a substrate for P-glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 345-349.	2.4	123
115	Drug metabolism and drug toxicity. <i>Inflammopharmacology</i> , 2001, 9, 183-199.	3.9	3
116	Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptentation and T-cell proliferation in vivo. <i>British Journal of Pharmacology</i> , 2001, 133, 295-305.	5.4	115
117	Plasma Cysteine Deficiency and Decreased Reduction of Nitrososulfamethoxazole with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1929-1938.	1.1	62
118	Biomimetic Fe(II)-Mediated Degradation of Arteflene (Ro-42-1611). The First EPR Spin-Trapping Evidence for the Previously Postulated Secondary Carbon-Centered Cyclohexyl Radical. <i>Journal of Organic Chemistry</i> , 2000, 65, 1578-1582.	3.2	59
119	Immunological Principles of Adverse Drug Reactions. <i>Drug Safety</i> , 2000, 23, 483-507.	3.2	127
120	Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. <i>British Journal of Pharmacology</i> , 1999, 126, 1393-1407.	5.4	126
121	Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. <i>British Journal of Pharmacology</i> , 1998, 125, 159-167.	5.4	22
122	Synthesis of the 8-aminoquinoline antimalarial 5-fluoroprimaquine. <i>Tetrahedron</i> , 1998, 54, 4615-4622.	1.9	30
123	Safety assessment of peroxide antimalarials: clinical and chemical perspectives. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 521-529.	2.4	41
124	Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective. <i>Chemical Research in Toxicology</i> , 1998, 11, 969-988.	3.3	260
125	Idiosyncratic Drug Reactions. <i>Clinical Pharmacokinetics</i> , 1996, 31, 215-230.	3.5	81
126	Lack of association between schizophrenia and the CYP2D6 gene polymorphisms. <i>American Journal of Medical Genetics Part A</i> , 1996, 67, 236-237.	2.4	14

#	ARTICLE	IF	CITATIONS
127	The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. British Journal of Clinical Pharmacology, 1996, 42, 347-353.	2.4	34
128	Clinical Pharmacokinetics of Tacrine. Clinical Pharmacokinetics, 1995, 28, 449-457.	3.5	52
129	Effects of Fluorine Substitution on Drug Metabolism: Pharmacological and Toxicological Implications. Drug Metabolism Reviews, 1994, 26, 605-643.	3.6	125
130	The Effect of Fluorine Substitution on the Metabolism and Antimalarial Activity of Amodiaquine. Journal of Medicinal Chemistry, 1994, 37, 1362-1370.	6.4	78
131	The Role of Active Metabolites in Drug Toxicity. Drug Safety, 1994, 11, 114-144.	3.2	69
132	A Simple and Convenient Method for the Oxidation of Sulphides. Synthetic Communications, 1993, 23, 1507-1514.	2.1	34
133	Drug-Protein Conjugation and its Immunological Consequences. Drug Metabolism Reviews, 1990, 22, 87-144.	3.6	114
134	Effect of rifampicin and isoniazid on vitamin D metabolism. Clinical Pharmacology and Therapeutics, 1982, 32, 525-530.	4.7	93
135	Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clinical Pharmacology and Therapeutics, 1981, 30, 363-367.	4.7	66
136	Metabolic Mechanisms. , 0, , 57-75.		0